Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to
receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects
completing the 48 week placebo-controlled period will receive open-label treatment with once
daily inhaled molgramostim for 48 weeks.